Introduction
Mdm2 binding protein (MTBP), a 104 kDa protein with no known functional motifs, was identified through a yeast two-hybrid screen to bind to the E3 ubiquitin ligase Mdm2 (Boyd et al., 2000) , a regulator of the p53 tumor suppressor (Marine and Lozano, 2010) . MTBP overexpression inhibited cell-cycle progression in a p53-independent, Mdm2-dependent manner after nocodazole treatment (Boyd et al., 2000) . A subsequent study showed that MTBP regulates p53 through modulation of Mdm2 ubiquitin ligase activity (Brady et al., 2005) . Specifically, overexpression of MTBP in tumor cell lines increased Mdm2 ubiquitin ligase activity increasing p53 degradation, and suppression of MTBP expression had the opposite effect. To determine the physiological role of MTBP, we generated mice lacking Mtbp . Mtbp heterozygous mice were viable and did not have any obvious defects. However, loss of both alleles of Mtbp was embryonic lethal. In contrast to Mdm2 deletion, the lethality of Mtbp deletion could not be rescued by loss of p53 , suggesting that Mtbp may not regulate Mdm2 and consequently p53 in vivo. Regardless of the Mtbp/Mdm2 relationship, decreased Mtbp expression has been linked to tumor metastasis , and the chromosomal region where MTBP lies is frequently amplified in human colorectal cancer and multiple myeloma (Carrasco et al., 2006; Martin et al., 2007) . Therefore, the function of MTBP in relationship to Mdm2 and p53 and in tumorigenesis is currently unclear.
Cell cycle and apoptosis are critical regulators of tumor development. Deletion of E2F1, a transcription factor essential for proliferation, inhibits c-Myc-induced B-cell lymphomagenesis through upregulation of the cell-cycle inhibitor p27 and suppression of cell-cycle progression (Baudino et al., 2003) . Moreover, reduced levels of ornithine decarboxylase (ODC), a transcriptional target gene of c-Myc required for polyamine synthesis, leads to decreased proliferation and inhibition of Myc-induced B-cell lymphoma development (Nilsson et al., 2005) . It is well established that Myc induces apoptosis in primary B cells, in part, by activating the ARF/Mdm2/p53 tumor suppressor pathway (Eischen et al., 1999) . Myc activates ARF, which inhibits Mdm2 causing p53 activation and apoptosis. Inactivation of ARF or p53 or overexpression of Mdm2 are frequent events detected in B-cell lymphomas that arise in mice overexpressing Myc (Em-myc transgenics) (Eischen et al., 1999) . Moreover, mice that are deficient in ARF or p53 or overexpress Mdm2 have an acceleration of lymphoma development due to a reduction in B-cell apoptosis (Eischen et al., 1999; Schmitt et al., 1999; Alt et al., 2003; Wang et al., 2008) . In contrast, Mdm2 heterozygosity inhibits Myc-induced lymphomagenesis due to increased p53-dependent B-cell apoptosis (Alt et al., 2003) , which can be rescued with loss of one allele of ARF (Eischen et al., 2004) . Therefore, genes that influence Mdm2, as Mtbp is postulated to do, should have a significant effect on Myc-induced apoptosis and tumor development. However, our data show that loss of one allele of Mtbp did not impact apoptosis or function through Mdm2, yet lymphoma development in Mtbp þ /À Em-myc transgenic mice was inhibited. Mtbp heterozygous cells had reduced rates of Myc-induced proliferation and decreased ability to upregulate Myc target genes necessary for cell growth. Our results indicate that Mtbp regulates Myc-induced lymphomagenesis not through Mdm2, but in cooperation with Myc.
Results

Mtbp expression is regulated by mitogens, oncogenes and cell cycle
To obtain a better understanding of Mtbp, we explored how Mtbp expression was regulated. The G1 cell-cycle arrest induced by depleting serum from cultured p53 À/À mouse embryo fibroblasts (MEFs) resulted in a dramatic decrease in Mtbp protein expression with a concomitant increase in the cell-cycle inhibitor p27, which is upregulated in G1 (Figure 1a) . Re-addition of serum back to serum-starved MEFs restored Mtbp expression as cells left G1 and moved into S phase (Figure 1b) . Similar results were observed in wild-type and ARF-null MEFs (data not shown). Overexpression of cyclin D or cyclin E or of the oncogenes c-Myc or E2F1, which drive cells into S phase, led to an increase in MTBP protein expression in human carcinoma cells and murine fibroblasts (Figure 1c ; data not shown). In contrast, expression of the cell-cycle inhibitors, p21 cip1 or p16
Ink4a
, which arrest cells in G1, resulted in decreased MTBP protein expression (Figure 1d ). Therefore, pro-proliferative signals upregulated and anti-proliferative signals downregulated Mtbp protein expression in human and murine cells, and this occurred independent of ARF and p53. These results suggest a positive role for Mtbp in cell growth.
Mtbp transcription is induced by Myc
To address whether the increase in Mtbp protein levels from serum and oncogenes was due to changes in Mtbp transcripts, we evaluated RNA levels. Mtbp/MTBP mRNA, as measured by quantitative real-time PCR (qRT-PCR) or northern blot, was significantly reduced by serum deprivation or after overexpression of p21 (Figures 2a and b) . Increased MTBP mRNA was detected with the re-addition of serum to serum-starved cells or overexpression of Myc or E2F1 (Figure 2b ). Two bands are visible in the E2F1 lane, which could indicate an alternatively spliced form of MTBP, but at this time it is unclear. Mtbp mRNA expression was also induced in vivo by c-Myc. qRT-PCR showed significantly elevated Mtbp mRNA in spleens of Mtbp
Em-myc transgenic mice, which overexpress c-Myc specifically in B cells, compared to levels in Mtbp þ / þ nontransgenic littermate spleens (Figure 2c ). There were also increased levels of Mtbp mRNA in Mtbp þ /À Em-myc spleens compared to levels in nontransgenic Mtbp þ /À spleens. Interestingly, Mtbp levels in Mtbp þ / þ Em-myc spleens were higher than those in Mtbp þ /À Em-myc spleens (Figure 2c ). To investigate whether Mtbp is directly induced by Myc, we generated murine fibroblasts expressing a 4-hydroxytamoxifen (4-OHT) regulatable form of Myc (MycER) (Littlewood et al., 1995) and treated them with the protein synthesis inhibitor cycloheximide. Within 30 min of MycER activation by 4-OHT, Mtbp mRNA expression increased (Figure 2d ), indicating that new protein synthesis was not required for Myc to induce Mtbp mRNA. There were modestly higher basal Mtbp levels in the MycER expressing cells in the absence of 4-OHT, likely due to the slight leakiness of the MycER construct. These results show that Myc may directly regulate Mtbp mRNA expression.
Mtbp regulates Myc-induced lymphomagenesis independent of Mdm2
It was reported that MTBP levels impact Mdm2 expression and function (Brady et al., 2005) . Because increased Mdm2 levels accelerate and decreased Mdm2 levels inhibit lymphoma development in Em-myc transgenic mice due to dysregulation of p53 (Alt et al., 2003; Wang et al., 2008) , we generated Mtbp þ /À Em-myc mice to evaluate lymphoma development. Mtbp þ /À Em-myc mice had a profound delay in lymphoma development compared to wild-type Em-myc littermates (Figure 3 ; P ¼ 0.0004, log-rank test To determine whether a deficiency in Mtbp would also inhibit the rapid lymphoma development in p53 þ /À Em-myc mice (Alt et al., 2003) and the contribution of p53 to Mtbp function, we generated p53
Em-myc mice accelerated lymphomagenesis to rates analogous to those of p53 Figure 3a) ; the mean survivals of both genotypes were 30 days. Thus, reduced levels of Mtbp suppressed Myc-induced lymphomagenesis, but the effect was abrogated by deletion of one p53 allele. These data imply that p53 functions downstream of Mtbp or that loss of p53 dominates B-cell transformation and supersedes any effect Mtbp haploinsufficiency has in Myc-induced lymphomagenesis.
The levels of p53 accessible to Mdm2 are regulated by ARF levels in Em-myc mice (Eischen et al., 2004) . If Mtbp regulates Mdm2, then altering the amount of ARF present should impact the ability of Mtbp to regulate Mdm2; we generated ARF
Em-myc transgenics to test this concept. In contrast to ARF
Em-myc mice (Eischen et al., 2004) , loss of one allele of ARF did not restore lymphoma latency in Mtbp þ /À Em-myc mice to wild-type Em-myc rates ( Figure 3b ). In fact, ARF
Em-myc mice rapidly developed lymphoma and had a similar mean survival to ARF
Em-myc littermates (60 versus 62 days, respectively). Therefore, Mtbp levels did not impact the ability of ARF to regulate Mdm2. To assess this concept further, we evaluated loss of heterozygosity (LOH) of the wild-type allele of
Em-myc lymphomas analyzed, including three that had also deleted the knockout allele of ARF (Figure 4a ), a frequency analogous to that in ARF þ /À Em-myc lymphomas (77% (Eischen et al., 1999) ). If Mtbp regulates Mdm2, the expected frequency of ARF LOH in the ARF
Em-myc lymphomas should have been similar to the 44% observed in lymphomas from ARF
Em-myc transgenics (Eischen et al., 2004) . These genetic results indicate that Mtbp function is not influenced by ARF status, and that Mtbp does not appear to be functioning through Mdm2.
Another means to evaluate whether Mtbp levels are regulating Mdm2 function in vivo is to analyze Mtbp
Em-myc lymphomas for p53 inactivation and Mdm2 levels. Of note, half of the Mdm2
Em-myc lymphomas have mutated p53 (Alt et al., 2003) . As previously reported for Em-myc lymphomas (Eischen et al., 1999) , p53 overexpression resulting from a mutation was present in a quarter of the lymphomas analyzed from Mtbp þ / þ Em-myc mice (data not shown). Similarly, 26% (7 of 27) of the lymphomas analyzed from Mtbp þ /À Em-myc transgenics contained mutant p53 ( Figure 4b ). All mutations fell within the DNA-binding domain of p53, including one lymphoma (MT616) that had a nonsense mutation resulting in a truncated p53 that was not detected by western blot. Only one of 27 Mtbp þ /À Em-myc lymphomas (MT163) had deleted p53 (Figure 4c ), the same frequency as that observed in Mtbp þ / þ Em-myc lymphomas. Biallelic ARF deletions were detected in 19% (5 of 27) of Mtbp þ /À Em-myc lymphomas (Figure 4d ), which is similar to the frequency of ARF deletions in wild-type Em-myc lymphomas (Eischen et al., 1999) . At least one of the three isoforms of Mdm2 was overexpressed in 62% (17 of 27) of the Mtbp þ /À Em-myc lymphomas (Figure 4b ), which was analogous to the frequency in Mtbp þ / þ Em-myc lymphomas. The levels of Mtbp protein in the lymphomas did not correlate to Mdm2 levels or p53 status. Moreover, Southern blots showed there was no LOH of the wild-type allele of Mtbp in Mtbp þ /À Em-myc lymphomas, and Mtbp was not deleted in Mtbp þ / þ Em-myc lymphomas (Figure 4e ). Therefore, loss of one allele of Mtbp did not result in increased p53 activation, leading to an increased frequency of p53 mutations or deletions in Mtbp þ /À Em-myc lymphomas, as would be expected if Mtbp regulated Mdm2. Moreover, Mdm2 levels were not influenced by Mtbp levels, and ARF deletions occurred at a normal frequency. Therefore, the data indicate Mtbp does not regulate Mdm2 or the ARF/Mdm2/p53 pathway during Myc-induced lymphomagenesis. 
The number of mice in each group is denoted by 'n' values. Lymphoma was documented in all mice. (Figure 5a ; data not shown). These results are in contrast to those obtained with Mdm2 þ /À bone marrow, which underwent apoptosis in culture (Alt et al., 2003) . Western blots showed lower levels of Mtbp protein in Mtbp þ /À pre-B cells in comparison to Mtbp þ / þ pre-B cells, whereas Myc and Mdm2 levels were equivalent in both genotypes (Figure 5a ). Because Mtbp expression is regulated by factors that induce growth (Figure 1) , and IL-7 is essential for pre-B-cell growth and survival, we evaluated the susceptibility of Mtbp þ /À pre-B cells to cytokine deprivation-induced apoptosis. Mtbp þ /À pre-B cells underwent apoptosis from IL-7 deprivation at the same rate as Mtbp þ / þ pre-B cells (Figure 5b ). Therefore, pre-B cells with decreased levels of Mtbp grew and underwent spontaneous apoptosis at normal rates, and were equally as sensitive to apoptosis from growth factor deprivation as wild-type pre-B cells.
Reduction of MTBP expression inhibits Myc-induced lymphomagenesis
To determine whether reduced Mtbp levels impact Myc functions, we evaluated Myc-induced apoptosis.
Pre-B cells were infected with a bicistronic retrovirus encoding MycER and green fluorescent protein (GFP). Both wild-type and Mtbp þ /À GFP þ pre-B cells underwent apoptosis at a similar rate following MycER activation with 4-OHT (Figure 5c ). We also assessed Myc-induced apoptosis in cultures of pre-B cells from Em-myc mice. Bone marrow cultures from Mtbp þ /À Em-myc and Mtbp þ / þ Em-myc littermates before any detectable disease consistently had similar numbers of dead or dying cells (data not shown). In addition, overexpression of Myc results in DNA breaks, which is thought to contribute to apoptosis and chromosomal instability (Vafa et al., 2002; Ray et al., 2006; Wang et al., 2008) . We evaluated metaphases from splenocytes from Mtbp þ /À Em-myc and Mtbp þ / þ Em-myc littermates before detectable lymphoma. There were similar percentages of metaphases with DNA breaks (chromosome and chromatid) and aneuploidy (greater or less than 40 chromosomes) in both genotypes (Figure 5d ). Therefore, decreased Mtbp levels did not appear to influence Myc-induced apoptosis, DNA breakage or chromosomal instability.
Loss of one allele of Mtbp inhibits Myc-driven proliferation As an oncogene, increased levels of Myc force proliferation; consequently, we evaluated Myc-driven B-cell growth. Bone marrows from Mtbp þ /À Em-myc and Mtbp þ / þ Em-myc littermates before any detectable Myc overexpression in the B-cell compartment of wild-type Em-myc mice leads to increased numbers of pre-B cells, which escape the bone marrow and are detected in the spleens of these mice (Langdon et al., 1986) . If decreased levels of Mtbp inhibit Myc-induced proliferation, we postulated that B-cell numbers would be altered in To further investigate the decreased Myc-induced proliferation of Mtbp-deficient cells, we evaluated the expression of four Myc transcriptional targets that are necessary for proliferation after Myc activation. MEFs from Mtbp þ /À and Mtbp þ / þ littermates were infected with the bicistronic retrovirus encoding MycER and GFP. MEFs were chosen for these experiments, because in the presence of serum, they proliferate when MycER is activated instead of undergoing apoptosis. Equal levels of MycER and GFP were detected in both genotypes of MEFs, and both grew at similar rates (Figure 6d ; data not shown). Activation of MycER with 4-OHT in the GFP þ wild-type MEFs resulted in the induction of ODC, carbamoyl phosphate synthetase 2/aspartate transcarbamylase/dihydroorotase (CAD), nucleophosmin (NPM) and nucleolin (NCL) in 3h (Figure 6d ). In contrast, in the GFP þ Mtbp þ /À MEFs, these Myc target genes showed a significantly reduced induction of expression after MycER activation. Similar results were obtained up to 8 h after MycER activation (data not shown). Therefore, decreased expression of Mtbp resulted in a reduction of Myc-mediated transcription of genes necessary for proliferation.
As a separate independent measure of Mtbp's role in proliferation and to further test the contribution of p53 to Mtbp function, we knocked down Mtbp expression in p53 À/À MEFs with Mtbp-specific siRNAs. Within 48 h, MEFs transfected with a pool of four different Mtbp-specific siRNAs showed an approximately 90% reduction in Mtbp expression, a larger decrease in Mtbp to that in Mtbp þ /À cells, compared to control 
The number of total metaphases analyzed is indicated at the bottom of each bar. Breaks were chromosome or chromatid. Aneuploidy is defined as any metaphase having more or less than 40 chromosomes. w 2 -Test was used to determine significance.
J Odvody et al ( Figure 6e ). Control siRNA did not impact cell growth, whereas MEFs with the Mtbp-specific siRNAs showed a significant reduction in proliferation 96 h after transfection. There was no detectable difference in apoptosis between the samples (data not shown). Therefore, loss of Mtbp expression suppressed proliferation in a p53-independent manner.
Mtbp is overexpressed in lymphomas
Our results suggest that Mtbp expression contributes to Myc functions necessary for growth and transformation, and is induced by Myc, and thus, we postulated Mtbp expression would be increased in lymphomas that overexpress Myc. Mtbp mRNA levels as determined by qRT-PCR were significantly elevated in Em-myc lymphomas compared to Mtbp levels in untransformed Em-myc splenocytes (Figure 7a) . Similarly, protein levels of Mtbp were also increased in Em-myc lymphomas. There were also significantly elevated levels of MTBP mRNA and protein in human B-cell lymphoma cell lines, as compared to three normal human lymphoid tissue controls (Figure 7b ). In addition, there were increased levels of MTBP in human Burkitt lymphomas that have MYC translocations, as well as in the human diffuse large B-cell lymphoma (DLBCL) cell lines, which 
-test). (c) Total numbers of B cells (B220
þ /CD19 þ ) or B-cell subsets in spleens of the indicated genotypes. Each bar represents four to six mice of each genotype. Asterisks denote statistically significant differences (*P ¼ 0.02; **P ¼ 0.0006, t-test). Representative dot plots of CD19-PE versus IgM-FITC gated on total lymphocytes from spleens. (d) Relative mRNA levels of the indicated gene transcripts were determined by qRT-PCR in Mtbp þ /À and Mtbp þ / þ MycER expressing MEFs after MycER activation with 4-OHT (*P ¼ 0.0005, **P ¼ 0.003, ***P ¼ 0.002; t-test). All data were generated in triplicate and normalized to b-actin levels. The levels of MycER were determined by western blot. (e) p53 À/À MEFs were transfected with control siRNA (Ctrl) or a pool of Mtbp-specific siRNAs. MTS assays were performed at intervals (*P ¼ 0.0003, t-test) and protein lysates were western blotted. Protein lysates from 293T cells transfected with a vector encoding Mtbp (M) or empty vector (V) were controls (1/6 of the amount of protein of the other samples).
frequently overexpress Myc. Therefore, B-cell lymphomas express increased levels of MTBP, possibly due to its role in proliferation, and thus, it may contribute to lymphomagenesis.
Discussion
A previous overexpression study has implicated Mdm2, and consequently p53, in mediating Mtbp functions (Brady et al., 2005) . However our unbiased genetic approach has revealed that Mdm2 appears to have little to do with Mtbp function. Using the Em-myc transgenic mouse model, which has well-established pathways of tumor development, we have shown that Mtbp is a novel regulator of tumor development and that decreased levels of Mtbp significantly inhibited lymphoma development in a manner different from that when Mdm2 or p53 levels are altered. Although both Mtbp and Mdm2 heterozygous Em-myc mice had profound delays in tumor development, here we have made the novel finding that the extended tumor latency of both mice was caused by two distinct mechanisms. Specifically, cells from Mtbp þ /À mice were impaired in their ability to respond to Myc overexpression, resulting in decreased proliferation and delayed tumor development. In contrast, Mdm2 þ /À B cells are hyperresponsive to Myc overexpression and undergo p53-dependent apoptosis causing a delay in tumorigenesis (Alt et al., 2003) . If reduced levels of Mtbp lead to decreased levels of Mdm2 as was reported (Brady et al., 2005) , then Mtbp þ /À Em-myc mice should have had increased B-cell apoptosis and a high frequency of p53 mutations in the lymphomas that arose. However, there was no significant increase in apoptosis of Mtbp þ /À cells when Myc was overexpressed, and the frequency of p53 mutations and deletions in Mtbp þ /À Em-myc lymphomas was similar to that of wild-type Em-myc lymphomas. In addition, loss of one allele of ARF, which restored lymphoma latency in Mdm2 þ /À Em-myc mice to that of wild-type Em-myc mice (Eischen et al., 2004) , only accelerated lymphoma latency in Mtbp þ /À Em-myc mice to the rate observed for ARF þ /À Em-myc mice. Notably, deletion of p53, which rescues the Mdm2-null lethality, did not rescue Mtbp À/À embryos . Moreover, Mtbp þ /À thymocytes had a normal p53 response after g irradiation . Combined, the data show that Mtbp does not function through Mdm2, but it is clearly a regulator of Mycinduced tumorigenesis.
Determining the role of decreased levels of Mtbp in mediating the delay in lymphoma development was challenging, because Mtbp did not appear to function through Mdm2 or impact apoptosis. However, because Mtbp expression was increased by pro-proliferative signals from growth factors and oncogenes and decreased when cells were arrested, this suggested Mtbp may participate in proliferation. The decreased proliferation we detected after knockdown of Mtbp expression supported this concept. We also observed that under conditions of hyperproliferative signals from the oncogene Myc, decreased Mtbp expression had significant effects on Myc function. Specifically, cells from Mtbp þ /À mice were impaired in their ability to respond to Myc overexpression, resulting in decreased proliferation and transcriptional activation of Myc target genes necessary for cell growth. This was reflected in Figure 7 Increased Mtbp expression in murine and human lymphomas. (a, b) qRT-PCR and western blots were performed with splenocytes (before detectable disease) and B-cell lymphomas from wild-type Em-myc transgenic mice (a) and human B-cell lymphoma lines (Burkitt lymphomas, white bars; DLBCL, gray bars) and normal human lymphatic tissues (spleen; lymph node, LN; peripheral blood lymphocytes, PBL, black bars) (b). Protein lysates from 293T cells transfected with an Mtbp-expressing vector (M) or empty vector (V) were controls (1/6 of the amount of protein of the other samples). qRT-PCR data were generated in triplicate and normalized to b-actin levels.
Reduction of MTBP expression inhibits Myc-induced lymphomagenesis
Em-myc mice by a significantly reduced expansion of pre-B cells normally observed in Em-myc mice. Previously, B cells with a decreased ability to proliferate from Myc overexpression have impaired Myc-induced lymphomagenesis. For example, deletion of E2F1 or loss of one allele of ODC led to an inhibition of Mycinduced proliferation of MEFs or B cells, respectively (Baudino et al., 2003; Nilsson et al., 2005) . Em-myc mice lacking E2F1 or heterozygous for ODC had a delay in B-cell lymphomagenesis that was attributed to reduced proliferation. We observed a decrease in the ability of Myc to upregulate ODC and other genes necessary for proliferation when Mtbp was heterozygous, which could explain the reduced rates of Myc-mediated proliferation in Mtbp þ /À Em-myc B cells. Therefore, a decrease in Mycinduced proliferation should account for the significant delay in B-cell lymphoma development in Mtbp þ /À Em-myc mice. However, we cannot rule out the possibility that Mtbp contributes to transformation in other ways as well. In addition, the biochemical mechanism by which Mtbp impacts Myc proliferative and transformation functions is unresolved. If Mtbp is a direct transcriptional target of Myc, as our data suggests, Mtbp could influence proliferation downstream of Myc. We have also detected Mtbp in the nucleus and associated with chromatin (CME, unpublished data); thus, Mtbp could directly or indirectly affect Myc transcriptional functioning. Although additional studies are needed to define the biochemical mechanism of Mtbp function, our results do show that Mtbp is regulated by Myc and has a critical role in proliferation mediated by Myc.
Our data indicate that Mtbp regulates Myc-induced lymphoma development in a manner that is consistent with an oncogene rather than a tumor suppressor. Specifically, decreased expression of Mtbp inhibited Myc-induced proliferation and tumor development. Mtbp was not deleted in wild-type Em-myc lymphomas, nor was there LOH of Mtbp in Mtbp þ /À Em-myc lymphomas. In another study, Mtbp
mice had a similar tumor latency as p53 þ /À mice . Therefore, Mtbp does not appear to be a classic tumor suppressor, as was originally proposed (Boyd et al., 2000) . Instead, Mtbp levels were elevated in B-cell lymphomas from mice and humans. These data are consistent with the observation that the region that encodes MTBP is frequently amplified in human colorectal cancers and multiple myeloma (Carrasco et al., 2006; Martin et al., 2007) . Moreover, public microarray databases show increased MTBP mRNA in many human cancers as compared to normal tissues. Therefore, mounting data indicate Mtbp overexpression is selected for and likely contributes to tumorigenesis, and thus Mtbp may be oncogenic. However, there is also data suggesting that decreased levels of Mtbp contribute to tumor metastasis in p53 heterozygous mice . Although the biochemical function of Mtbp in metastasis in p53 þ /À mice is unresolved, the requirements of Mtbp in metastasis are likely to be different than that for Mtbp in Myc-induced proliferation and tumorigenesis. It will be important in the future to determine whether Mtbp is oncogenic in its own right or a critical partner of an oncogene such as Myc, and its precise role in metastasis.
Materials and methods
Mice
Congenic C57Bl/6 Em-myc transgenic mice were from Dr Alan Harris (Walter and Eliza Hall Institute, Melbourne, Australia) and Dr Charles Sidman (University of Cincinnati, Cincinnati, OH, USA), and ARF À/À mice were from Dr Martine Roussel and Dr Charles Sherr (St Jude Children's Research Hospital, Memphis, TN, USA). Mtbp þ /À (C57Bl/6X129/Sv backcrossed onto C57Bl/6 at least five generations) mice were crossed to male Em-myc transgenics to generate F1's. F1's were crossed to generate F2's for analysis. F2's were also crossed to ARF À/À or p53 À/À mice to generate mice deficient in ARF or p53. Mice were carefully followed, and at signs of disease were killed. Statistical significance was determined by log-rank tests. All experiments with mice were approved by the Vanderbilt Institutional Animal Care and Use Committee (IACUC) and followed all federal and state rules and regulations.
Culture and infection of primary pre-B cells and lymphocyte phenotype analysis Primary pre-B-cell (CD43
) cultures were generated from bone marrow of 5-to 8-week-old mice. Pre-B cells were infected with MSCV-MycER-IRES-GFP and GFP þ cells were sorted by fluorescence-activated cell sorting (FACS). Phenotypic analyses of pre-B cells, whole spleens, bone marrow and lymphomas were performed with fluorescently linked antibodies from Southern Biotechnology (Birmingham, AL, USA) or BD Pharmingen (San Jose, CA, USA) and flow cytometry. All procedures were previously described (Eischen et al., 1999) .
Viability, apoptosis, proliferation, cell-cycle and chromosome analysis Viability after explanation of bone marrow into IL-7 containing medium, after the addition of 1 mM 4-OHT (Sigma, St Louis, MO, USA) to the culture medium of MycER expressing pre-B cells or after IL-7 deprivation was determined at specific intervals by Trypan blue dye exclusion. Apoptosis and cell cycle was measured with propidium iodide staining and analysis on a FACScalibur. Quantification of fragmented (sub-G1) DNA was performed with CellQuest (BD Immunocytometry Systems, San Jose, CA, USA). The percentage of cells in each phase of the cell cycle was determined by ModFIT (Verity House Software, Topsham, ME, USA). Proliferation was determined by BrdU incorporation as previously described . MTS assays were performed at intervals as per manufacturer's protocol (Promega, Madison, WI, USA) after transfection of four replicates of siRNAs (ontarget SMART pools for Mtbp or nontargeting control; Dharmacon, Lafayette, CO, USA) with Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA). Metaphases of splenocytes were analyzed for breaks and aneuploidy as previously described .
Western and Southern blotting
Murine pre-B cells, lymphomas and spleens, and normal human lymph node, spleen, peripheral blood lymphocytes and lymphoma cell lines were lysed as previously described (Zindy et al., 1998) . Antibodies specific for p19 ARF (GeneTex,
